People · Operator
Named in public records as an officer, director or promoter · active 2019–2019 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Kiadis Pharma N.V. | — | Biotechnology | Series B | $18.4M | $728.4M | 2019 |
Mark Wegter at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mark Wegter on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Martijn Kleijwegt | 1 | 2 |
| Berndt Modig | 1 | 2 |
| Dr. Robert Soiffer | 1 | 1 |
| Otto Schwarz | 1 | 1 |
| Subhanu Saxena | 1 | 1 |
| Scott A. Holmes | 1 | 1 |
| James A. Joy | 1 | 1 |
| Mark A. Schaefer | 1 | 1 |
| Arthur Lahr | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.